News & press releases
Milestones, financings and clinical progress as we advance RTN-001 for patients with uncontrolled and resistant hypertension.
2026
Retension priced its upsized initial public offering of 3,750,000 shares of common stock at $12.00 per share, for expected gross proceeds of $45.0 million. Shares are expected to begin trading on the Nasdaq Capital Market on October 9, 2026 under the ticker symbol “RTSN.”
Read moreDistinguished physicians and investigators in hypertension, cardiovascular disease, nephrology and cardiovascular trials join to advise the RTN-001 program as the Phase 2b study proceeds.
Read moreAppointments strengthen clinical and regulatory leadership as the Company advances RTN-001 through its Phase 2b trial.
Read moreSeasoned executives join Retension with deep cardiovascular clinical development experience and financial leadership as RTN-001 advances through Phase 2b testing.
Read more2025
Retension closed a $15 million Series B to advance RTN-001 for uncontrolled and resistant hypertension and announced issuance of a U.S. patent covering the lead candidate.
Read more2024
Oversubscribed Series A to fund clinical development of RTN-001 in resistant and uncontrolled hypertension.
Read more